Cherry Biotech Secures $2.5 Million in Grant Funding for Revolutionizing Drug Discovery and Personalized Medicine with Organ-on-Chip Technology

Cherry Biotech is excited to announce that it has successfully raised $2,500,000 in funding to further its mission of revolutionizing drug discovery and personalized medicine. As a pioneering biomedical technology company specializing in "Organ on Chip" solutions, Cherry Biotech is dedicated to replacing traditional animal testing methods with advanced in vitro models that reconstruct human tissue using organoids. With the assistance of this funding, Cherry Biotech aims to enhance its proprietary CUBIX platform, which allows pharmaceutical companies, biotech firms, and healthcare providers to create complex, immunocompetent human vascularized organ models and tumor microenvironments. This innovative approach empowers researchers to evaluate drug candidates more accurately by mimicking human physiology and pathophysiology over extended periods. The unique CUBIX technology, which transforms standard 2D multi-well plates into fully functional 3D cell cultures, stands at the forefront of addressing ethical concerns surrounding animal experimentation while aligning seamlessly with existing industry workflows. Securing this funding is a significant milestone for Cherry Biotech, especially as it continues to be recognized as a leading innovator by the Paris Saclay Cancer Cluster, an initiative designed to accelerate advancements in oncology. The funds will also facilitate ongoing research and development efforts, partnerships, and market expansion, ultimately equipping the healthcare sector with cutting-edge tools for safer, more effective therapies. With this investment, Cherry Biotech is poised to make a significant impact on the future of drug development and patient care.